A Case of Angiosarcoma of the Nasal Cavity Successfully Treated with Recombinant Interleukin‐2

Angiosarcoma of the nasal cavity and paranasal sinuses: a rare case report

“…Etiology is unknown and known to have the risk factors like chronic lymphedema, radiotherapy, vinyl chloride exposure, trauma and telangiectatic skin lesions. 5,6 Diagnosis is made by histopathological examination of the biopsy from the mass and confirmation by immunohistochemical stains which shows positivity to CD 34, CD 31,Ulex europaeus agglutinin I and factor VIII antigen. Treatment of choice is the radical surgical excision of the mass with free margins followed by radiotherapy.…”

Sinonasal angiosarcoma

“…The sinonasal site is exceptional, as only 24 cases have been reported since 1974 [2,3] in patients ranging in age from 8 to 81 years (our patient was 53 years old) with a male predominance (16 men for 8 women in the 24 reported cases). No known aetiology or risk factors have been identified, but telangiectasia, trauma and chronic oedema have been proposed [4,5]. Clinically, the tumour presents with similar symptoms to those of malignant sinonasal tumours: initially unilateral rhinological syndrome (epistaxis, blocked nose and rhinorrhoea) and, at a more advanced stage, tumour syndrome with invasion F. Es-Sbissi et al / European Annals of Otorhinolaryngology, Head and Neck diseases xxx (2015) xxx-xxx of vital structures (eyeball, brain and infratemporal fossa).…”

“…Other treatment modalities have been tried, such as chemotherapy, radiosurgery (gamma knife) [4], and interleukins [2][3][4][5]. However, no standardized therapeutic management has been defined in view of the limited number of published cases and the absence of comparative studies.…”

The effect of interleukin-2 on canine peripheral nerve sheath tumours after marginal surgical excision: a double-blind randomized study

“…Treatment with rhIL2 did not significantly influence the MFI, RFI, or OS. In contrast, it has been reported to have a beneficial effect in various types of tumours in humans [16,17] and animals [25,29-31,35,36,39], providing a 6% complete response (CR) and 10% partial response (PR) in one study [16] or a 50% decrease in nasal angiosarcoma size in another [17]. In other studies, mice with inoculated lymphoma or mastocytoma treated intraperitoneally with IL-2 achieved a 70–90% CR [29-31], cattle with ocular squamous cell carcinoma treated with peritumoural IL-2 achieved a 69% CR [35], and horses with sarcoid tumours achieved a 14% PR and 43% CR with intratumoural IL-2 [36].…”

“…Local rhIL2 therapy (intratumoural, peritumoural, or intravesical) is suggested to be more effective than systemic rhIL2 therapy and to have fewer side effects [17,20,23]. It has proven effective in the treatment of soft tissue sarcomas (STS) [22,23], malignant lymphoma [24], and gastrointestinal tumours [25] in humans, mice, and dogs.…”